Postmenopausal osteoporosis Market

Increasing demand for bisphosphonates is driving the market growth

The capacity of the bisphosphonates family of drugs to stop bone density loss and hence reduce fracture risk by 50% is predicted to account for the biggest proportion of the market. Moreover, most patients are able to take bisphosphonates over the long term. For instance, as per an article published in April 2021, named 'Bisphosphonate Prescriptions for Osteoporosis: Concerns In regards to Dangers and Side Effects,' by restraining osteoclast action, bisphosphonates diminish bone resorption, and various examinations have shown the way that this group of medications can increment bone thickness and lower break risk in those with low bone thickness.

Because most patients with osteoporosis receive frequent prescriptions for them, it is anticipated that they will hold a sizable portion of the market under investigation.

Several bisphosphonates are often used to avoid and treat postmenopausal osteoporosis, including alendronate, risedronate, ibandronate, and zoledronic acid. A new regimen, including the intravenous approach, is being studied; positive trial results might further drive the bisphosphonate business throughout the anticipated time frame. The average five-year prescription for bisphosphonates lasts, and the drug's bone-protective effects last long after the course of therapy is stopped. Therefore, it is anticipated that the bisphosphate category would have a sizable market share in the postmenopausal osteoporosis market due to the considerations above.

Additionally, targeting certain processes involved in bone metabolism, such as sclerostin inhibition or the RANK ligand pathway, is the goal of biological treatments. Biologics can improve bone production and reduce bone resorption by carefully adjusting these pathways, providing a more focused and efficient method of treating osteoporosis, which is driving the market CAGR. In patients who are at high risk of fractures or who do not respond well to standard pharmacological medications, biologic therapies have proven to be more effective than traditional ones.

This increased effectiveness may result in better results, such as decreased risk of fracture and increased density of bone mineral.

Furthermore, as per information distributed by the Worldwide Menopause Society (IMS), in 2021, more than 200 million ladies are assessed to experience the ill effects of osteoporosis, and 1 of every three ladies matured more than 50 is supposed to encounter osteoporosis fracture. Due to the previously mentioned factors, the concentrated market is supposed to develop over the estimated period. Thus driving the Postmenopausal Osteoporosis market revenue.

The global demographic shift towards an aging population is a significant factor propelling the Global Postmenopausal Osteoporosis Market Industry. As life expectancy rises, the number of postmenopausal women is increasing, leading to a higher prevalence of osteoporosis. This demographic trend necessitates enhanced healthcare services and treatment options tailored to older women. The market's growth trajectory is closely linked to this aging population, as healthcare systems adapt to meet the needs of this demographic. Consequently, the industry is likely to experience sustained growth as it addresses the challenges posed by an increasingly elderly population.

Innovations in pharmacological treatments for postmenopausal osteoporosis are significantly influencing the Global Postmenopausal Osteoporosis Market Industry. New medications, including bisphosphonates, hormone replacement therapy, and monoclonal antibodies, have emerged, offering improved efficacy and safety profiles. These advancements not only enhance patient outcomes but also encourage healthcare providers to adopt these therapies more widely. The anticipated compound annual growth rate (CAGR) of 5.39% from 2025 to 2035 underscores the potential for continued growth in this sector, as new therapies become available and existing treatments are optimized.

Growing awareness regarding osteoporosis and its consequences among healthcare professionals and the general public is driving the Global Postmenopausal Osteoporosis Market Industry. Educational campaigns and screening initiatives have led to earlier detection and treatment of osteoporosis, which is crucial for preventing fractures and other complications. As awareness increases, more women are seeking preventive care and treatment options, contributing to market growth. This shift in perception is expected to enhance the market's value, with the industry poised for expansion as more individuals recognize the importance of bone health.

Supportive regulatory frameworks and clinical guidelines for osteoporosis management are shaping the Global Postmenopausal Osteoporosis Market Industry. Governments and health organizations are actively promoting the development and accessibility of osteoporosis treatments through favorable policies and funding initiatives. These regulations encourage research and development in the field, facilitating the introduction of new therapies and improving patient access to existing treatments. As regulatory bodies continue to prioritize osteoporosis management, the market is expected to benefit from increased investment and innovation, further driving its growth.

The increasing incidence of osteoporosis among postmenopausal women is a primary driver of the Global Postmenopausal Osteoporosis Market Industry. As women age, particularly after menopause, the risk of developing osteoporosis escalates due to hormonal changes that affect bone density. It is estimated that by 2024, the market will reach a valuation of 10.2 USD Billion, reflecting the urgent need for effective treatments and preventive measures. This trend is likely to continue, with projections indicating that by 2035, the market could grow to 18.2 USD Billion, highlighting the growing demand for osteoporosis management solutions.

By region, the study provides market insights into North America, Europe, Asia-Pacific, and the Rest of the World. The North American Postmenopausal Osteoporosis market will dominate this market because of its developed medical care framework, presence of significant industry players, high diagnosis and therapy rate, more patient consistency, and huge patient base. The US contributes the most extreme offer in North America. About 18.8% of women who were 50 years of age or older had osteoporosis, according to data released by the Centers for Disease Control and Prevention (CDC) in 2021.

Sedentary lifestyles and bad eating and drinking habits are expected to contribute to the pervasiveness even further. Approximately 71 million Americans are expected to have reduced bone density and osteoporosis by 2030, according to the Public Osteoporosis Establishment.

Further, the major countries studied in the market report are the US, Canada, Germany, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.

Figure 2:  POSTMENOPAUSAL OSTEOPOROSIS MARKET SHARE BY REGION 2023 (USD Billion)

Source: Secondary Research, Primary Research, Market Research Future Database and Analyst Review

Europe's Postmenopausal Osteoporosis market accounts for the second-largest market share. Europe's population is among the oldest in the world, and a significant number of postmenopausal women live in regions where osteoporosis is more common. The demographic shift towards an aging population creates an important market for osteoporosis prevention, diagnosis, and treatment. Further, the German Postmenopausal Osteoporosis market held the largest market share, and the UK Postmenopausal Osteoporosis market was the fastest-growing market in the European region.

The Asia-Pacific Postmenopausal Osteoporosis Market is expected to grow at the fastest CAGR from 2024 to 2032. Numerous nations in the Asia Pacific are putting resources into extending their healthcare framework, further developing admission to healthcare administrations, and reinforcing primary care systems. This development of healthcare facilities and services upgrades opportunities for osteoporosis screening, analysis, and therapy. Moreover, China’s Postmenopausal Osteoporosis market held the largest market share, and the Indian Postmenopausal Osteoporosis market was the fastest-growing market in the Asia-Pacific region.

The industry's leading players will keep investing heavily in R&D to expand their product lines, which will propel the growth of the postmenopausal osteoporosis market. Contractual contracts, mergers and acquisitions, increased investments, collaboration with other companies, and the production of new products are examples of significant market developments. To increase their worldwide reach, market players also take part in a variety of strategic initiatives. In order to survive and expand in a more competitive and dynamic market, the Postmenopausal Osteoporosis industry must offer reasonably priced products and services.

One of the main strategies manufacturers use in the worldwide Postmenopausal Osteoporosis market is local manufacturing, which expands the market sector and helps customers by lowering operating costs. Some of the biggest medical benefits in recent years have come from the Postmenopausal Osteoporosis sector. Major players in the Postmenopausal Osteoporosis market, including Pfizer Inc., Amgen, F.

Hoffmann-La Roche Ltd, Novartis AG, Chugai Pharma China Co., Ltd., Teva Pharmaceutical Industries Ltd., Fresenius Kabi AG, Hikma Pharmaceuticals PLC, GlaxoSmithKline plc, Sun Pharmaceutical Industries Ltd, Paras Biopharmaceuticals Finland Oy, Ligand Pharmaceuticals Incorporated, and Eli Lilly and Company, and others, are attempting to increase market demand by investing in research and development operations.

Pfizer Inc (Pfizer) discovers, creates, makes, and markets biopharmaceuticals. The organization offers items to treat different circumstances, such as cardiovascular, metabolic, and pain, ladies' well-being, malignant growth, inflammation, resistant problems, and rare illnesses. It additionally gives clean injectable drugs, biosimilars, active pharmaceutical ingredients (APIs), and agreement-producing services. Pfizer sells its items through wholesalers, retailers, medical clinics, individual supplier workplaces, facilities, government organizations, and drug stores. Pfizer Inc. brought back to the U.S. market DUAVEE (conjugated estrogens/bazedoxifene), a menopausal hormone treatment with estrogen, in June 2023 with improved packaging.

This return follows a voluntary recall due to a packaging problem that had nothing to do with any worries about the efficacy or safety of the product. It is anticipated that this relaunch plan will address the packaging concerns and increase sales income.

Amgen Inc., a biotechnology business, finds, makes, produces, and distributes state-of-the-art human meds to treat patients with hazardous sicknesses. It makes state-of-the-art prescriptions to address afflictions connected with the heart, hematological and oncology, irritation, bone well-being, neurological sicknesses, and nephrology. To make merchandise that uses state-of-the-art human hereditary qualities, the association inspects the difficulties presented by sickness and appreciates the standards of human science. Amgen mainly supplies pharmaceutical wholesale wholesalers in the United States with its goods. Additionally, it markets some items directly to customers through collaborations with other businesses and direct-to-consumer channels.

Amgen's latest findings from real-world research in 2023 show that Prolia was very successful in lowering the risk of fracture in individuals with postmenopausal osteoporosis.